<DOC>
	<DOCNO>NCT02500550</DOCNO>
	<brief_summary>The purpose study determine whether repeat dose administration ATIR101 safe effective infused patient hematologic malignancy follow T-cell depleted stem cell graft relate haploidentical donor . All patient plan receive two ATIR101 dose 2×10E6 viable T-cells/kg , unless second dose reduce halt safety reason .</brief_summary>
	<brief_title>Safety Efficacy Two Doses ATIR101 , T-lymphocyte Enriched Leukocyte Preparation Depleted Host Alloreactive T-cells , Patients With Hematologic Malignancy Who Received Hematopoietic Stem Cell Transplantation From Haploidentical Donor</brief_title>
	<detailed_description>Study CR-AIR-008 exploratory , open-label , multicenter study . After sign informed consent , patient receive hematopoietic stem cell transplantation ( HSCT ) relate , haploidentical donor , follow first ATIR101 infusion dose 2×10E6 viable T-cells/kg 28 32 day HSCT . Patients receive second ATIR101 infusion dose 2×10E6 viable T-cells/kg 70 74 day HSCT . To evaluate safety second dose administration , first 6 patient treat evaluated occurrence dose limit toxicity ( DLT ) , define acute GvHD grade III/IV within 120 day post HSCT ( within 42 day second ATIR101 infusion case prior dose delay ) . If within first 6 patient DLT observe , treatment remain 9 patient continue two ATIR101 dose 2×10E6 viable T cells/kg . If within first 6 patient least 2 patient show DLT , second ATIR101 infusion adjust dose 1×10E6 viable T cells/kg . If one next 3 patient treat low dose DLT observe , second ATIR101 infusion halt remain patient give single dose ATIR101 . All patient treat ATIR101 follow 12 month HSCT . Assessments perform weekly visit day first ATIR101 infusion ( Week 4 ) 6 week second ATIR101 infusion ( Week 16 ) , monthly visit 4 6 month HSCT , every 3 month 6 12 month HSCT .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Any following hematologic malignancy : Acute myeloid leukemia ( AML ) first remission highrisk feature second high remission Acute lymphoblastic leukemia ( ALL ) first remission highrisk feature second high remission Myelodysplastic syndrome ( MDS ) : transfusiondependent , intermediate high IPSSR risk group Karnofsky performance status ≥ 70 % Eligible haploidentical stem cell transplantation accord investigator Male female , age ≥ 18 year ≤ 65 year Availability fully match related unrelated donor follow donor search Diffusing capacity carbon monoxide ( DLCO ) &lt; 50 % predict Left ventricular ejection fraction &lt; 50 % ( evaluate echocardiogram MUGA ) AST &gt; 2.5 x ULN ( CTCAE grade 2 ) Bilirubin &gt; 1.5 x ULN ( CTCAE grade 2 ) Creatinine clearance &lt; 50 mL/min ( calculate measure ) Positive HIV test Positive pregnancy test ( woman childbearing age ) Prior allogeneic HSCT Estimated probability survive less 3 month Known allergy component ATIR101 ( e.g. , dimethyl sulfoxide ) Known presence HLA antibody nonshared donor haplotype Any condition , opinion investigator , make patient ineligible study Inclusion Criteria Donor : Haploidentical family donor 2 3 mismatch HLAA , B and/or DR locus unshared haplotype Male female , age ≥ 16 ≤ 75 year ( If applicable , local legal requirement donor age 18 follow ) Eligible donation human blood blood component accord local requirement regulation Eligible donation accord transplantation center Exclusion Criteria Donor : Positive pregnancy test nursing ( woman childbearing age ) Positive viral test HIV1 , HIV2 , HBV , HCV , Treponema pallidum , HTLV 1 ( test ) , HTLV2 ( test ) , WNV ( test )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Haploidentical stem cell transplantation</keyword>
	<keyword>Graft versus host disease</keyword>
	<keyword>Immune reconstitution</keyword>
	<keyword>Alloreactive T-cells</keyword>
	<keyword>Photodynamic treatment</keyword>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Transplant-related mortality</keyword>
</DOC>